You searched for "intravitreal"
High dose (2.5mg) bevacizumab for postradiation cystoid macular oedema
The authors present a retrospective, interventional case series investigating the efficacy of high dose (2.5mg/0.1ml) intravitreal bevacizumab in the treatment of persistent postradiation (Iodine-125 plaque brachytherapy for uveal melanoma) cystoid macular oedema (CME). Persistent CME was defined as increased or...
IVTA use in Behçet’s disease
This study aimed to evaluate the efficacy and safety of intravitreal triamcinolone acetonide (IVTA) injection (4mg/0.1ml) in controlling posterior segment inflammation in patients with Behçet’s disease. Medical records of consecutive patients diagnosed with Behçet’s who underwent IVTA between July 2005...
Culture positivity of needles for IVT injections
Given the worldwide use of intravitreal (IVT) injections, the authors of this paper set out to evaluate the rate of culture positivity of the needles used in routine IVT injections and compare this positivity between 27-gauge and 30-gauge needle tips....
Rebound phenomenon after IVT triamcinolone acetonide for macular oedema
In this retrospective study, the authors report the rebound phenomenon after intravitreal triamcinolone acetonide (IVTA) injection for macular oedema secondary to diabetic retinopathy (DR) and central (CRVO) or branch retinal vein occlusion (BRVO). The incidence of a rebound phenomenon was...
Stereotactic radiotherapy for polypoidal choroidal vasculopathy
Polypoidal choroidal vasculopathy (PCV) is a variant of neovascular AMD. It is a disease of choroidal vasculature characterised by abnormal branching vascular network with aneurysmal dilatations (polyps). Features of PCV include pigment epithelial detachments (PED), subretinal fluid (SRF) accumulation and...3rd Ophthalmic Drug Delivery Summit
Translating Long Lasting Efficacy & Less Invasive Retinal Drug Delivery The importance of matching the right drug delivery route to the right ophthalmic disease is more pressing than ever. The 3rd Ophthalmic Drug Delivery Summit is the premier gathering for...Diabetes macular oedema in pregnancy self-resolving postpartum
*Equally contributing co-first authors. Diabetic macular oedema (DMO) is a common clinical presentation to ophthalmology clinics. Ample evidence exists for management of DMO in non-pregnant patients. However, there is a paucity of evidence on the optimal management of DMO in...
Ozurdex use in noninfectious uveitis
Burkholder et al. reported the practice patterns of 45 respondents of approximately 176 surveyed members of the American Uveitis Society regarding the use of the Ozurdex implant. Most respondents performed the injection in either a procedure (41.0%) or clinic (23.1%)...
RTP801 as a neuroprotective and axon regenerative treatment
This paper describes the neuroprotective and axon regenerative effects of siRTP801, which is a translatable small-interfering RNA (siRNA) targeting mTOR negative regulator; RTP801, through in-vivo and in-vitro models. In-vivo studies involved an optic nerve crush rat model with intravitreal injections...
ARN in North Africa
Acute retinal necrosis (ARN) is a rare cause of uveitis. This paper aims to outline the clinical features of 12 patients with ARN in a referral centre in Tunisia, North Africa. A retrospective review of case notes was carried out....
Outcomes of ‘treat and extend’ for neovascular AMD
The authors report on 24-month outcomes of anti-vascular endothelial growth factor (anti-VEGF) therapy using a ‘treat and extend’ regime for treatment-naïve neovascular age-related macular degeneration (nAMD). Data for this study was collected from the Fight Retinal Blindness observational registry based...
